GO:0001717 conversion of seryl-tRNAsec to selenocys-tRNAsec

The Gene Ontology term GO:0001717, conversion of seryl-tRNAsec to selenocys-tRNAsec, defines the enzymatic modification of serine charged on a specialized tRNA(ser) species into selenocysteine, the 21st proteinogenic amino acid. This process is a prerequisite for the synthesis of selenoproteins, a family of proteins that contain selenocysteine and are essential for antioxidant defense, redox signaling, and thyroid hormone metabolism. Unlike standard amino acids, selenocysteine is not synthesized as a free amino acid but is produced directly on its tRNA, making this conversion a unique and critical step in translation. Researchers study GO:0001717 to understand how selenoproteins are made, how their synthesis is regulated, and how defects in this pathway contribute to human disease. The pathway involves multiple enzymes and cofactors that sequentially modify the seryl moiety on tRNAsec, ultimately yielding selenocysteinyl-tRNAsec that can be delivered to the ribosome. Because selenoproteins are involved in diverse cellular processes, perturbations in this conversion step have broad physiological consequences.

GO:0001717 is defined as the modification process that results in the conversion of serine, carried by a specialized tRNA(ser) (which can read a UGA anticodon), to selenocysteine. In other words, it is the set of biochemical reactions that transform the amino acid serine, while attached to its dedicated tRNA, into selenocysteine, which is then used in protein synthesis.

GO:0001717 is essential because it produces selenocysteine, the key building block for selenoproteins, which are critical for cellular antioxidant defense, redox homeostasis, and various metabolic processes. Without this conversion, selenoproteins cannot be synthesized, leading to impaired cellular protection against oxidative stress and contributing to diseases such as cancer, neurodegeneration, and cardiovascular disorders. Understanding this pathway provides insights into how organisms utilize selenium and how defects in selenocysteine synthesis can be targeted therapeutically.

The following genes and proteins are central to the conversion of seryl-tRNAsec to selenocys-tRNAsec and its regulation.

The conversion of seryl-tRNAsec to selenocys-tRNAsec is regulated at multiple levels. Selenium availability influences the expression and activity of enzymes in the pathway, such as PSTK and SEPSECS. Additionally, the pathway is subject to translational control via the SECIS element and its binding proteins, which modulate the efficiency of UGA recoding in response to cellular stress and selenium status. Post-translational modifications and feedback mechanisms may also adjust pathway flux to meet the demand for selenoproteins.

Mutations in SEPSECS, which catalyzes the final step of GO:0001717, cause pontocerebellar hypoplasia and other neurodevelopmental disorders characterized by impaired selenoprotein synthesis. Patients present with progressive microcephaly, intellectual disability, and cerebellar atrophy, highlighting the critical role of this pathway in brain development.

Altered expression of selenoproteins and enzymes in the selenocysteine synthesis pathway has been observed in various cancers. For example, reduced SEPSECS or PSTK levels may impair antioxidant defense, increasing oxidative stress and promoting tumorigenesis. Targeting this pathway is being explored for cancer therapy.

Selenoproteins such as glutathione peroxidases and thioredoxin reductases are crucial for cardiovascular health. Defects in the conversion of seryl-tRNAsec to selenocys-tRNAsec can lead to reduced selenoprotein levels, contributing to cardiomyopathy, endothelial dysfunction, and metabolic syndrome.

Ribo-seq allows genome-wide measurement of translation, including readthrough at UGA codons, to assess the efficiency of selenocysteine incorporation. It can reveal how perturbations in GO:0001717 affect selenoprotein synthesis.

RNA-seq quantifies mRNA levels of selenoproteins and pathway enzymes, providing insights into transcriptional regulation and compensatory responses. It is often combined with Ribo-seq for integrated analysis.

Mass spectrometry-based proteomics can identify and quantify selenoproteins, using specialized methods to detect selenocysteine-containing peptides. This validates the functional impact of pathway perturbations.

Reporter constructs with UGA codons followed by fluorescent proteins can measure selenocysteine incorporation in live cells. Imaging of tagged selenoproteins allows subcellular localization studies.

Researchers studying conversion of seryl-tRNAsec to selenocys-tRNAsec-related genes often need to determine whether a candidate gene is causally involved in selenoprotein synthesis, oxidative stress responses, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies with high precision and reproducibility.

GO:0001717, conversion of seryl-tRNAsec to selenocys-tRNAsec, is a fundamental biological process that enables the synthesis of selenocysteine and, consequently, all selenoproteins. Its importance spans antioxidant defense, neurodevelopment, cancer, and cardiovascular health, making it a compelling area of research. Advances in CRISPR-based models and multi-omics methods are accelerating our understanding of this pathway and its role in disease, offering new opportunities for therapeutic intervention.